Home Neoplasma 2020 Neoplasma Vol.67, No.2, p.394–401, 2020

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.2, p.394–401, 2020

Title: Low pretreatment PNI correlates with worse survival in patients with stage III/IV NSCLC who received chemotherapy
Author: Y. Shen, H. Li, Z.Q. Yuan, M.Y. Ren, S.L. Yu, Y.D. Liao, J.J. Cai, C. Liu, B.C. Chen, A.H. Wu, G.F. Li, L. Xie

Abstract: The aim of this study was to investigate the prognostic value of the prognostic nutritional index (PNI) on the long-term survival of non-small cell lung cancer (NSCLC) patients who received platinum-based chemotherapy. Data on nutritional parameters and clinicopathological characteristics [e.g., albumin, total protein, body mass index (BMI), eastern cooperative oncology group (ECOG) performance status, stage, pathology, treatment strategy] were analyzed and retrospectively correlated with overall survival (OS). The PNI was calculated based on the concentration of albumin and lymphocyte count [10 × albumin, (g/dl) + 0.005 × lymphocyte (count/mm)]. A receiver operating characteristic curve (ROC) analysis was used to find the optimal cut-off value of PNI. Univariate and multivariate analyses were used to evaluate the prognostic value of PNI. A total of 186 patients met the inclusion criteria. The optimal cut-off value for PNI was 50.45. Compared with the parameters of the low PNI group (n=76), high PNI was significantly associated with adenocarcinoma type, stage III, better ECOG and comprehensive treatment modality. The univariate analysis demonstrated that OS was superior when PNI ≥50.45, albumin ≥35 g/l, platelet-lymphocyte ratio (PLR) ≥163 and ECOG

Keywords: prognostic nutrition index, survival, non-small cell lung cancer, platinum-based chemotherapy
Published online: 21-Mar-2020
Year: 2020, Volume: 67, Issue: 2 Page From: 394, Page To: 401
doi:10.4149/neo_2019_190401N284
Price: 19.20 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.